Emcure Pharmaceuticals Limited has announced its schedule for participation in upcoming analyst and investor meetings. The company disclosed that its officials will attend several conferences starting in late May 2026.

The first meeting is scheduled for Tuesday, May 26, 2026, in Mumbai. This event is the Ambit Capital Titans of Tomorrow Conference, where the company will engage in both group and one-on-one meetings.

Schedule of Meetings

The following table outlines the proposed schedule for participation in investor conferences by company officials:

Disclosure and Compliance

The company clarified that the schedule provided is tentative and subject to changes due to exigencies on the part of investors or the company. Emcure Pharmaceuticals further stated that no unpublished price sensitive information is proposed to be shared or discussed with the aforementioned analysts or investors during these meetings. The intimation was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Emcure Pharmaceuticals has disclosed that it has been assigned an Environmental, Social, and Governance (ESG) rating of 21 for the financial year 2024-25. This rating was voluntarily and independently assigned by NSE Sustainability Ratings & Analytics Limited, a SEBI-registered ESG Rating Provider. The assessment was conducted based on information available in the public domain regarding the company's operations and practices.

The intimation was submitted to the National Stock Exchange of India Limited and BSE Limited on May 08, 2026. The disclosure was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A Para A of Schedule III and a SEBI circular dated January 30, 2026. This regulation mandates timely disclosure of material events that could impact the company or its stakeholders.

Key Details of the Disclosure

The following table summarizes the key details regarding the ESG rating assignment:

The company received specific information about this rating via email on May 07, 2026. The communication was signed by Amruta Amit Yangalwar, the Company Secretary & Compliance Officer of Emcure Pharmaceuticals Limited, bearing ICSI Membership Number A25687.